264 pages | 42 Color Illus. | 51 B/W Illus.
This internationally renowned author team provides a unique and thorough analysis and distillation of the endocannabinoid system and its relationship to abdominal obesity, diabetes, and cardiovascular disease. The endocannabinoid system (ECS) plays an important role in cardiometabolic risk, as well as modulating energy balance, feeding behavior, hepatic lipogenesis, and perhaps glucose homeostasis. Evidence suggests that the ECS is overactive in human obesity and dyslipidemia.
Critical to the management of cardiometabolic risk, this new, timely book provides practical overviews and management guidance on many important topics, including:
Preface. Intro. Health Hazard of Obesity. Abdominal Obesity and the Metabolic Syndrome: An Int'l Perspective. Abdominal Obesity and the Metabolic Syndrome. Abdominal Obesity, Metabolic Syndrome, and CVD. Abdominal Obesity in Type 2 Diabetes. Abdominal Obesity in Cardiology. Abdominal Obesity and Sleep Apnea.
Abdominal Obesity and Hypertension. Visceral Adiposity, IR, and Type 2 Diabetes. Visceral Adiposity, Liver Fat, and Atherogenic Dyslipidemia. Visceral Adiposity and Inflammation. Visceral Adiposity and Fibrinolysis-Thrombosis. Visceral Adiposity, Menopause, and Related Cardiometabolic Risk. Visceral Adiposity, Ethnicity and Related Cardiometabolic Risk. The Endocrine Function of Adipose Tissue. FFA Metabolism in Visceral Obesity. Liver Fat and Visceral Obesity. Animal Models of Visceral Obesity. FFA Metabolism and Visceral Adiposity. Physical Activity / Exercise.
Is there an Optimal Diet for the Mgt of Visceral Obesity. Can we Change the Lifestyle of High-Risk Patients. Can We Change the Body Fat Distribution Phenotype? Lessons from PPARgamma Agonists. Can We Change the Body Fat Distribution Phenotype? Lessons from studies in Transsexuals. Subcutaneous Fat as a Metabolic Risk. The EC System and Central Control of Energy Balance -- Appetitive Aspects. The EC System and Central Control of Energy Balance -- Consommatory Aspects. The EC System and the HPA Axis. The EC System and Satiety. The EC System in the GI Tract. The EC System in the Adipose Tissue and Endocrine Pancreas. The EC System in the Immune System. The EC System in the Liver. The EC System and Cardiovascular Func. The EC System, Energy Expenditure. Potential Impact of the Diet. The Overactive EC System. The Overactive EC System. CB1 Blockade in the Mgt of Abdominal Obesity. CB1 Blockade, Insulin Resistance and Type 2 Diabetes. CB1 Blockade in Atherogenic Dyslipidemia of AO. CB1 Blockade and Hypertension. CB1 Blockade to Prevent Type 2 Diabetes. Future Developments 1. Future Developments 2. Conclusions and Clinical Perspectives.